Compare ANNX & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | MFA |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 1.0B |
| IPO Year | 2020 | N/A |
| Metric | ANNX | MFA |
|---|---|---|
| Price | $5.36 | $9.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $16.50 | $11.05 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,320.74 | $10.02 |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.85 | $8.78 |
| 52 Week High | $7.18 | $10.57 |
| Indicator | ANNX | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 46.59 |
| Support Level | $4.80 | $9.37 |
| Resistance Level | $5.61 | $9.70 |
| Average True Range (ATR) | 0.28 | 0.15 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 55.96 | 46.69 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.